Keywords: Canada, Intellectual property monopolies, Patents, CETA, European Union, CGPA, Rx&D

Canada must reject EU's demands for longer IP monopolies, says CGPA

Article | 27 June 2012

New data on R&D spending in Canada by brand-name drug companies provides further proof that there is no ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in